Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.58 |
| ▸ | FDPS | P14324 | 1/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 10/20 | 0.55 |
| ▸ | PTPRA | P18433 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30186102 | 1.00 | KDM4E (0.63) | KDM4ENAPRTFDPSTBXAS1PTPRA | |
| SCHEMBL12238430 | 1.00 | KDM4E (0.63) | KDM4ENAPRTFDPSTBXAS1PTPRA | |
| SCHEMBL5174680 | 1.00 | KDM4E (0.63) | KDM4ENAPRTFDPSTBXAS1PTPRA | |
| SCHEMBL6885074 | 0.85 | KDM4E (0.62) | KDM4ENAPRTFDPSTBXAS1LMNA | |
| SCHEMBL12906734 | 0.84 | FDPS (0.54) | KDM4ENAPRTFDPSTBXAS1LMNA | |
| SCHEMBL7384333 | 0.84 | CYP1A2 (0.62) | KDM4ENAPRTFDPSTBXAS1LMNA | |
| SCHEMBL9737253 | 0.83 | KDM4E (0.53) | KDM4ENAPRTFDPSTBXAS1LMNA | |
| SCHEMBL7675391 | 0.83 | KMO (0.54) | KDM4ENAPRTTBXAS1 | |
| SCHEMBL14665158 | 0.81 | FDPS (0.51) | KDM4ENAPRTFDPSTBXAS1LMNA | |
| SCHEMBL124365 | 0.81 | SLC7A5 (0.65) | KDM4ENAPRTFDPSTBXAS1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195417-B2 | Rheology additives based on hydroxylated di-or tri-amides and mixtures therof | ARKEMA FRANCE (FR) | 2025-01-14 | — | — | US | claimed |
| EP-3947343-A1 | RHEOLOGY ADDITIVES BASED ON HYDROXYLATED DI- OR TRI-AMIDES AND MIXTURES THEREOF | ARKEMA FRANCE (FR) | 2022-02-09 | — | — | EP | claimed |
| CN-113614065-A | Rheological additive based on hydroxylated diamides or triamides and mixtures thereof | 阿科玛法国公司 | 2021-11-05 | — | — | CN | claimed |
| WO-2020201638-A1 | RHEOLOGY ADDITIVES BASED ON HYDROXYLATED DI- OR TRI-AMIDES AND MIXTURES THEREOF | ARKEMA FRANCE (FR) | 2020-10-08 | — | — | WO | claimed |
| EP-1326993-B1 | PRODUCTION OF ALPHA-HYDROXY-CARBOXYLIC ACIDS USING A COUPLED ENZYME SYSTEM | EXCELSYN MOLECULAR DEV LTD (GB) | 2007-05-23 | — | — | EP | claimed |
| EP-3947343-B1 | RHEOLOGY ADDITIVES BASED ON HYDROXYLATED DI- OR TRI-AMIDES AND MIXTURES THEREOF | ARKEMA FRANCE (FR) | 2025-05-07 | — | — | EP | disclosed |
| EP-4168488-A2 | RHEOLOGICAL ADDITIVES BASED ON DIAMIDE, FUNCTIONALIZED POLYMER AND WAX | ARKEMA FRANCE (FR) | 2023-04-26 | — | — | EP | disclosed |
| CN-115702210-A | Rheological additive based on diamides, functionalized polymers and waxes | 阿科玛法国公司 | 2023-02-14 | — | — | CN | disclosed |
| CN-114728464-A | Thermoplastic polymer composition for constructing 3D articles | 阿科玛法国公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-3947343-A1 | RHEOLOGY ADDITIVES BASED ON HYDROXYLATED DI- OR TRI-AMIDES AND MIXTURES THEREOF | ARKEMA FRANCE (FR) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021255164-A2 | RHEOLOGICAL ADDITIVES BASED ON DIAMIDE, FUNCTIONALIZED POLYMER AND WAX | ARKEMA FRANCE (FR) | 2021-12-23 | — | — | WO | disclosed |
| CN-113614065-A | Rheological additive based on hydroxylated diamides or triamides and mixtures thereof | 阿科玛法国公司 | 2021-11-05 | — | — | CN | disclosed |
| EP-2319919-A1 | Nitrilases | Verenium Corporation (US) | 2011-05-11 | — | — | EP | disclosed |
| US-20100086986-A1 | Increased activity and stability at increased pH and temperature; making a chiral alpha -hydroxy acid molecule, a chiral amino acid molecule, a chiral beta -hydroxy acid molecule, or a chiral gamma-hydroxy acid molecule, from a molecule with a cyanohydrin moiety or an aminonitrile moiety | VERENIUM CORPORATION (US) | 2010-04-08 | — | — | US | disclosed |
| US-7651849-B2 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2010-01-26 | — | — | US | disclosed |
| US-20090176976-A1 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2009-07-09 | — | — | US | disclosed |
| EP-2039762-A2 | Nitralases | Verenium Corporation (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-1326993-B1 | PRODUCTION OF ALPHA-HYDROXY-CARBOXYLIC ACIDS USING A COUPLED ENZYME SYSTEM | EXCELSYN MOLECULAR DEV LTD (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2005123727-A1 | 3-ARYL-3-HYDROXY- AND 3-ARYL-3-OXOPROPIONIC ACID ESTERS AS FUNGICIDES | CROPSOLUTION, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050277663-A1 | 3-Aryl-3-hydroxy-and 3-aryl-3-oxopropionic acid esters as fungicides | ATP CAPITAL LP | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277663-A1 | 3-Aryl-3-hydroxy-and 3-aryl-3-oxopropionic acid esters as fungicides | CYP21A2, HAO1, AHR | KDM4E 1577/4885NAPRT 2922/4885FDPS 3135/4885 |
| US-20100086986-A1 | Increased activity and stability at increased pH and temperature; making a chiral alpha -hydroxy acid molecule, a chiral amino acid molecule, a chiral beta -hydroxy acid molecule, or a chiral gamma-hydroxy acid molecule, from a molecule with a cyanohydrin moiety or an aminonitrile moiety | ASPH, AHSA1, DNPH1 | KDM4E 3889/4885NAPRT 159/4885FDPS 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.